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Summary 
HLA-B27 subtypes share many structural features, including their pocket ]3, which interacts with 
a conserved Arg residue at the second position of B*2705-bound peptides. Subtypes differ among 
each other at other locations in the peptide binding site. In this study, metabolic labeling and 
radiochemical pool sequencing were used to address the following issues: (a) presence of the 
Arg 2 (R2) motif among peptides bound to the various HLA-B27  subtypes;  (b) influence of 
mutations inside and outside pocket B on this motif; and (c) the degree of similarity  among 
the peptide pools bound to the various B27 subtypes. Sequencing of Arg-labeled peptide pools 
extracted from B'2701 to B'2706, and from two site-directed mutants ofB'2705 with changes 
outside pocket B, indicated that all of these molecules bind peptides with Arg at position 2. 
Peptides from several mutants with changes altering the structure of pocket 13, and from one 
mutant at the pocket B rim, also retained the lk2 motif. However, this was absent in the peptide 
pool extracted from the M45 mutant, in which the negative charge of pocket B, conferred to 
HLA-B27 by Glu45, was canceled. These results indicate that alterations outside pocket B, and 
even disruption of the network of hydrogen bonds that stabilizes Arg binding in pocket B, do 
not impair binding of peptides bearing the R2 motif, but a nonconservative substitution at position 
45 does. As a substantial fraction of anti-B ~  cytotoxic T lymphocyte (CTL) clones crossreact 
with the M45 mutant (Villadangos, J., B. Galocha, D. L6pez, V. Cairo, andJ.A. L6pez de Castro. 
1992.J. Irnraunol. 149:505) this result suggests that determinant mimicry by nonidentical peptides 
may frequently account for unexpected CTL crossreactions. Metabolic labeling with various other 
amino acids and radiochemical sequencing revealed similarities, but also substantial differences, 
among the peptide pools from the various HLA-B27 subtypes. This strongly suggests that many 
peptides bind to multiple subtypes, but significant subsets of peptides bound to a given HLA- 
B27 subtype do not bind to other subtypes or do so with greatly altered effidency. These results 
indicate the importance of polymorphism outside pocket B in modulating peptide binding to 
HLA-B27. 
C 
lass I HLA molecules bind endogenous peptides  and 
present them at the cell surface to CTL. X-ray diffrac- 
tion studies have shown that the peptide binding site is a 
groove contributed by the oil and cz2 domains and formed 
by an eight-stranded B-pleated  sheet topped by two large 
or-helical regions (1, 2). This groove accommodates peptides, 
generally nonamers, in extended conformation (3, 4). For each 
class I molecule the peptide binding site can be described in 
terms of a series of pockets, six designated A to F in HLA-A2 
(5), that interact with individual peptide side chains. HLA 
polymorphism modulates the number, shape, and polarity 
of these pockets (6), and, in this way, determines the peptide 
binding specifidty of each class I HLA protein. 
Crystallographic analyses  of peptide/MHC complexes from 
HLA and H-2 molecules have revealed that most of the con- 
tacts between the MHC protein and the bound peptides are 
established with the peptide main chain and with both pep- 
tide termini. Other contacts involve some of the peptide side 
chains and the various pockets of the MHC molecule (7-9). 
The structure of these pockets determines the peptide side 
chains they can accommodate. The highly restrictive character 
of some pockets imposes the anchoring peptide motifs that 
characterize the type of peptides that can bind to a particular 
HLA molecule (10). Pocket 13, which binds peptide side chain 
2 (P2), is extremely well fit in HLA-B27 for interacting with 
Arg side chains, and there is no evidence that other residues 
can be accommodated (7, 11). Thus, Arg at position 2 (R2) 
is the major peptide motif among HLA-B27-bound peptides. 
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tide binding is the effect of variations in the structu~ of pockets 
on their capacity for accommodating particular peptide side 
chains.  For instance,  all HLA-B27 subtypes have the same 
pocket B structure,  although  some of the residues forming 
this pocket are very polymorphic among HLA-B antigens. 
By contrast,  HLA-B27 subtypes differ from one another by 
one or a few residues located in other pockets (12).  Thus, 
the peptide binding  specificity of HLA-B27 antigens must 
be assessed by examining the effects of changes in pocket B, 
and in other pockets, on the nature of bound peptides.  In 
this study we have examined the effect of mutations in pocket 
B on the capacity of binding peptides with the R2 motif. 
In addition,  we have compared the peptide pools bound to 
various HLA-B27 subtypes. The results indicate that changes 
outside pocket B do not alter the R2 motif. Some structural 
changes in pocket B, but not the change of Glu45 to Met, 
are also compatible with the R2 motif. In spite of sharing 
R2, the peptide pools bound to the various subtypes are sub- 
stantiaUy different,  indicating  the role of other pockets in 
the specificity of peptide binding  by HLA-B27. 
Materials  and Methods 
Cell Lines and Mutants.  Genomic DNA containing  B~ 
B'2703, and B'2706 generated by site-directed mutagenesis (13) 
were transfected into the class I-deficient HMy2.C1R cells by dec. 
troporation as previously described (14), followed by sdection with 
200/~g/ml of hygromyfin B (Sigma Chemical Co., St. Louis, MO). 
The B~  and B'2702 transfectant CIR cell lines were previ- 
ously described (14). Transfectant cell lines expressing high amounts 
of these HLA-B27 subtypes (Table 1) were used as source of material 
The following site-directed mutants derived from B~  were 
also used: Y9, A24, M45, N63, V67, Q70, A24V67, Y9QT0, and 
E152. These are designated with the one-letter code of the amino 
acid(s) introduced followed  by the corresponding residue number(s). 
Each mutant was expressed on HMy2.C1R cells after transfection. 
Most of these mutants  and transfectants have been previously de- 
scribed (14, 15). Yg, QT0, and Y9Q70 were obtained and trans- 
fected by the same procedure. HLA-B27-negative populations in 
Y9 and Y9Q70 were removed, following instructions  from the 
manufacturer, by positive sdection of the transfected population 
with goat anti-mouse antibody conjugated to Dynabeads M-450 
(Dynal, Oslo, Norway),  after incubating  the cells with the ME1 
(anti-B27, -B7, -B22) mAb (16). The expression levels of all the 
mutants, as estimated by FACS  ~ (Becton Dickinson & Co., Moun- 
tain View, CA) analysis, are shown in Table 1. 
The Wewak I (HLA-All, 24; B~  62) and JY (HLA-A2; 
B7) LCL were used as source of material for B*2704, and for HLA- 
A2 and HLA-B7, respectively. C1R transfectants and LCL were 
grown in DMEM supplemented with 5% heat-inactivated FCS 
and in tLPMI 1640, 25 mM Hepes buffer, and 10% FCS (all from 
Gibco Laboratories, Paisley, UK) respectively.  The B'2701, B~ 
and B'2706 transfectants were continuously maintained with 300 
/~g/ml of hygromycin. 
Isolation of Bios'2/ntheticaUy  Labeled HLA-boand Poptides.  2  x  107 
ceils were labeled in 10 ml of R.PMI 1640 lacking a given amino 
acid (tLPMI 1640 select-amino acid kit; Gibco Laboratories), sup- 
plemented with 5% dialyzed FCS and 250/zCi of that 3H-hbeled 
amino acid (Amersham Corp.,  Buckinghamshire,  UK), and in- 
cubated  overnight  at 37~  in 5%  COz.  For  [3SS]Met labeling, 
Met-deficient MEM (Gibco Laboratories) was used. The ceLls  were 
then  washed twice in 20 mM Tris/HC1 buffer, 150 mM NaC1, 
pH 7.5, and were lysed in the same buffer containing 0.5% NP-40 
(Sigma Chemical Co.) and a mixture of protease inhlbitors: 5 ~g/ml 
aprotinin,  10  /zg/rrd leupeptin,  10  Izg/ml  pepstatin  (all from 
Boehfinger,/~,,nhdm, Germany), 100 ~  iodoacetamich, 3 ng/ml 
EDTA,  2 mM PMSF (Sigma Chemical  Co.),  and 0.2%  NaN~ 
(Merck, Darmstadt,  Germany). After 1 h on ice the lysate was cen- 
trifuged in a microfuge for 45 min at 4~  The supernatant was 
divided in two aliquots, and 100 ~1 of ME1 (16) or PA2.1 (anti- 
HLA-A2) (17) mAb coupled to Sepharose was added to each ali- 
quot. After 3 h at 4~  in a rotary wheel, the immunoprecipitates 
were washed eight times: twice with NET buffer (0.05 M Tris/HCl, 
0.15 M NaC1, 5 mM EDTA, 0.02% NAN3, pH 7.4), containing 
0.5%  NP-40 and 1/10 saturated NaCI;  twice with NET, 0.5% 
NP-40, 1/20 saturated NaC1; twice with NET, 0.5% NP-40; and 
twice with NET alone. 
Washed immunoprecipitates were boiled at 100~  in 10% acetic 
acid, for 10 min.  After centrifugation  for 5 rain in a microfuge, 
the supernatant  was passed through  a microconcentrator  (Cen- 
tricon-3;  Amicon Corp.,  Danvers, MA) previously washed with 
10% acetic acid. The peptide fraction was concentrated in speed- 
vac to a volume of 100 ~1. HPLC profiles of the internally labeled 
peptide pools from B'2705 immunoprecipitates  showed a highly 
complex pattern,  indicating that the bulk of B27-bound peptides, 
and not a few major ones, were recovered with this procedure (not 
shown). 
Radiochemical Pool Sequencing.  Concentrated  peptide pools ex- 
tracted from each HLA immunoprecipitate  were sequenced with 
0.5 mg of OVA (Sigma Chemical Co.) carrier protein and 3 mg 
BioBrene Plus (Applied Biosystems Limited,  Warrington,  UK), 
in a gas-phase protein sequencer using the MAC program.  Each 
sequencer fraction was mixed with 3 ml of Universol ES (ICN 
Biochemicals, Irvine, CA) for counting on a liquid  scintillation 
counter. 
Results 
Assessment  of the R2 Motif in HLA-B27-bound Peptides by 
Radiochemical Sequencing.  The distribution of Arg residues 
among the peptides bound to B'2705 was examined by radi- 
ochemical  sequencing  of the peptide  pool after metabolic 
labding  with  [3H]Arg,  specific  immunoprecipitation  of 
HLA-B27, and acid extraction of the immunoprecipitated ma- 
terial (Fig.  1). The radioactivity profile showed a major peak 
at cycle 2, and signal significantly above background at cycles 
1 and 3.  On the basis  of crystallographic  and biochemical 
analyses  (7, 11), the vast majority, if not all,  of the endoge- 
nous peptides bound to B'2705 contain Arg at their second 
position.  Thus, radioactivity at position 2 reflects the pres- 
ence of Arg in essentially all the peptides in this pool. Radio- 
activity at cycle 1 ranged from 34 to 44% of that recovered 
at  cycle 2 in  three independent  experiments.  This  is  only 
slightly lower than the proportion of Arg residues at posi- 
tion  1 among 14 reported sequences from endogenous and 
viral peptides known to bind to B'2705,  which was 50% 
(11). The radioactivity at cycle 3, rdative to cycle 2, ranged 
from 32 to 51% in the three experiments. Because of carry- 
over from  the  previous cycle,  the  presence of Arg  in  this 
position cannot be assigned. Radioactivity at cycle 3 was some- 
what higher than the carry-over obtained upon radiochem- 
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Figure  1.  Radiochemical sequence analysis of the Arg-labeled peptide 
pools fzom HLA-B27 (B~  HLA-B7 (B~  and HLA-A2 (A~ 
3H dpm are plotted vs. cycle  number as the percent of the total counts 
recovered in all cycles  that are found at each given cycle. Peptides were 
extracted from specific  immunoprecipitates  obtained from metabolically 
labeled C1R transfectants  (B'2705), untransfected  CIR cells (mock),  and 
theJY (B*0702, A'0201) LCL, using the PA2.1 (for HLA-A2)  and ME1 
(for all others)  mAbs. For B*2705, results  from three independent  experi- 
ments are  represented. Total dpm  loaded into the  sequencer were 
18,000-20,000 (B'2705 and B'0702), 6,800 (A~  and 8,000 (mock). 
Total dpm recovered  after  each  sequencer  run were: 1,974, 2,424, and 2,036 
(B~  443 (mock), 2,990 (B*0702), and 572 (A~  The dpm re- 
covered in the control sequence  correspond to background, as they did 
not exceed  60 dpm at any cycle. 
ical sequencing of single peptides (18,  19), but was in the 
range obtained with pool sequencing of cold material (10). 
The absence of radioactivity at other cycles indicates that Arg 
is much less frequent at other positions than at position 2, 
as also observed among B~  peptides of known 
sequence (11). 
The specificity and sensitivity of this method for assessing 
the R2 motif was further examined by sequencing the Arg- 
labeled peptide pools from HLA-B7 or HLA-A2. The former 
antigen is predicted to lack pocket ]3, due to the presence 
of Tyr67 (7). HLA-A2 has a hydrophobic B pocket that binds 
aliphatic peptide side chains, predominantly Leu (5, 10). With 
the peptide pool from HLA-B7, specific signal was observed 
at cycles 1, 3, and 6, but not at cycle 2. Similarity, no radio- 
activity at cycle 2 was found upon sequencing the peptide 
pool from HLA-A2 (Fig.  1). 
These results show that radiochemical sequencing of Arg- 
labeled peptide pools can be used to analyze the presence of 
the R2 motif in HLA-B27-bound peptides and to detect this 
residue at other positions. 
Binding of  Arg-containing Peptides to HLA-B27 Variants with 
Unaltered Pocket  R  The same approach was used to analyze 
the distribution of Arg residues along the sequence of the 
peptides bound to the B'2701  to B'2706  subtypes, as well 
as to the E152 mutant. All these molecules have the same 
pocket B structure but differ from each other at one or more 
positions in other pockets (Table 1). The E152 mutant was 
examined because it is not recognized by most of the anti- 
B'2705  alloreactive CTL (14,  20). 
Cells expressing each of these proteins were metabolically 
labeled with  [3H]Arg,  and the corresponding B27-bound 
peptide pools were subjected to radiochemical sequencing. 
As shown in Fig. 2, the radioactivity profiles of all the pep- 
tide pools were similar to each other and to the peptide pool 
from B'2705 (Fig. 1). The major radioactivity peak was found 
at position 2, demonstrating that the K2 motif is conserved 
among the peptides bound to all of these HLA-B27 variants. 
In addition, radioactivity at cycles I  and 3, relative to cycle 
2, ranged from 43 to 52% and from 32 to 57%, respectively. 
These values  are comparable to those obtained in different 
experiments with B'2705-bound peptides, and therefore do 
not reflect detectable differences among the various peptide 
pools. Finally, no significant Arg-associated radioactivity was 
observed at other cycles. 
These results indicate that the HLA-B27 subtypes and E152 
mutant all bind peptides with the R.2 motif. Furthermore, 
subtype polymorphism, or the E152 mutation, does not re- 
sult in a detectable alteration of the frequency of Arg residues 
at other peptide positions. 
Binding of Arg-containing Peptides to HLA-B27 Pocket B 
Mutants.  Arg-hbded endogenous peptides were also isolated 
from a series of HLA-B27 mutants with one or two changes 
in pocket B (Table  1) expressed on C1R transfectant cells, 
and subjected to radiochemical pool sequencing. The results 
(Fig.  3)  are described below. 
First, the predominance of Arg at position 2 was main- 
tained in all mutants except M45.  In this mutant no Arg 
was detected at cycle 2, beyond that attributable to carry- 
over from cycle 1. This indicates that the substitution of Glu 
for Met at position 45 in HLA-B27 abrogates or greatly reduces 
the capacity of binding peptides with the R2 motif. By con- 
trast all other pocket B mutants retained this capacity 
Second, conspicuous radioactivity was found at cycle 1 in 
all mutants except N63.  This result indicates that most of 
the mutants retained the capacity of binding peptides with 
Arg at position 1, but the N63 mutation results in nearly 
undetectable amino-terminal Arg among the peptides bound 
to this mutant. 
Third, except for M45 and N63, the ratio of radioactivity 
between cycles 1 and 2 ranged from 48 to 70%.  This ratio 
was 35-52% in the peptides from B'2705 and other HLA- 
B27 molecules with unaltered pocket B (Figs.  1 and 2). The 
somewhat higher ratio found in some of the mutants, such 
as A24 (0,69)  and A24V67  (0,70),  is compatible with re- 
laxed structural constraints in their B pockets, so that pep- 
tides with some residue(s) other than Arg at position 2 might 
also be accommodated. However, the possibility that some 
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Subtype/mutant  Amino acid changes  Pocket"  Mean  channel  _+  SD  t 
B'2705  -  155  •  17 
B'2701  D74-*Y74  C/F  142  _+  30 
D77~N77  C/F 
L81~A81  C/F 
B'2702  D77~N77  C/F  155  •  22 
T80-+I80  C/F 
L81--*A81  C/F 
B'2703  Y59-*H59  A  151  •  22 
B'2704  D77--~$77  C/F  148  •  19s 
V152--E152  E 
B'2706  D77~$77  C/F  141  •  29 
Hl14-*D114  D,  E 
Dl16~Y116  C/F 
V152~E152  E 
Y9  H9-'*Y9  B  138  •  17 
A24  T24"-*A24  B  126  •  16 
M45  E45-'*M45  B  131  •  27 
N63  E63-'~N63  A,  B  160  •  20 
V67  C67--*V67  B  150  •  23 
Q70  K70-'*Q70  B  157  •  23 
A24V67  T24--~A24  B  119  •  17 
C67--*V67  B 
Y9Q70  H9~Y9  B  120  •  16 
K70-~Q70  B 
E152  V152"~E152  E  134  •  34 
HMy2.C1R  -  24  •  16 
" Pocket  assignments  are based on references 5 and 7.  The K70 side chain in HLA-B27 is oriented away  from pocket  B and forms  a salt bridge 
with D74 (7). 
* FACS  ~  analysis of transfectant  cell lines,  using the anti-HLA-B27 mAb ME1. 
$ B'2704 FACS  |  analysis was  performed  on the Wewak  I LCL. 
of the mutations in pocket B indirectly result in binding of 
an increased number of peptides with amino-terminal  Arg, 
regardless of their effect on the P,2 motif, cannot be ruled out. 
Fourth,  as in B'2705 and other subtypes, no significant 
radioactivity  was  observed beyond cycle 3  in  any  of the 
mutants. 
HLA-B27 Subtypes Bind Related but Substantially Different 
Peptide Sets.  The relatedness  among the B'2701- to B*2706- 
bound endogenous peptides was examined by radiochemical 
sequendng of the Lys-, Leu-, Ile-, Val-, and Met-labded pep- 
tide pools.  This approach reveals the amount  of an amino 
acid at one particular  position,  relative to other positions, 
among the peptides bound to a given HLA molecule. It does 
not reflect the absolute frequency of that residue at a partic- 
ular position,  as only a fraction of the total peptide pool is 
usually labded with  any given amino  acid. 
Sequencing of the Lys-labded peptide pool (Fig.  4) from 
B'2705 revealed radioactivity not attributable to carry-over, 
at cycles 1, 3, 4, 5, and, less dearly, 6 and 8. No Lys could 
be assigned at cycles 2, 7, and 9. This pattern was only par- 
tially maintained in the peptide pools from other B27 sub- 
types. For instance, radioactivity at cycle 4, relative to cycles 
1, 3, and 5, was substantially higher in B'2701 than in B'2705. 
In  B'2702,  Lys was less  abundant  at  position  1,  and  fig- 
nificantly more at cycle 8, relative to positions 3-6, than in 
B'2705.  Lys was predominant  at  positions  1,  3,  and 5 in 
B'2704,  and at  1 and 3, but  not  5,  in B'2706. 
Sequencing of Leu-labeled peptide pools revealed predom- 
inant radioactivity peaks at cycles 3 and 9, as well as radioac- 
tivity not accounted for by carry-over at cycles 5-7 in B'2705. 
Other subtypes showed a somewhat similar distribution of 
Leu, but significant differences in the relative proportions of 
this  residue were also evident,  e.g.,  the  increased relative 
proportion of Leu at cycle 7 in B'2704 and at cycle 4 in B'2706. 
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Figure  2.  Radiochemical~equence analysis of the Arg-labeled peptide  2o  2o 
pools from the B'2701 to B  2706 subtypes and the E152 mutant. These 
were obtained by immunoprecipitation from CIK transfectants,  ~:ept 
B'2704, which was obtained from the Wewak I LCL. Data are plotted 
as explained in Fig. 1. dpm loaded into the sequencer were 20,000 (8  2701, 
O~  O ~  B'2702, B'2703, and B'2706), 12,000 (B'2704), and 18,000 0/152). Total  1  s  lO  1  5  lO 
dpm recovered after sequencing are given in pamathesis within each panel.  CYCLE  N. 
The lie-labeled pool from B'2705 showed a predominant 
distribution of this residue at positions 3, 5, 6, and 7 upon 
sequencing. Some relevant radioactivity was also dear at cycle 
1. Again, within a general similarity, peptide pools from other 
subtypes showed some differences. For instance, the relative 
abundance oflle at position 1 was highest in the peptide pool 
from B'2706,  which also showed increased signal at cycle 
9. The relative amount of Ile at cycle 4 was also higher in 
B'2704 and B'2706. 
Pool sequencing from B'2705 allowed us to assign Val at 
every peptide position except 2, 7 (due to carry-over),  and 
9. As with other amino acids, the general pattern was con- 
served in the peptide pools from other subtypes,  although 
changes in the relative amounts of Val at the various posi- 
tions were clear. The most significant difference was the vir- 
tual absence of Val-associated radioactivity at cycle 3 in the 
peptide pools from B* 2704 and B* 2706. Other conspicuous 
differences were in the ratio ofdpm at cycles 7 and 8 in B'2705 
compared with B'2701 to B'2703, and the significantly higher 
signal at cycle 1 in B'2706, compared with other subtypes, 
especially B'2705. 
Met appeared predominantly  at cycles 1, 3, and 5 in B'2705, 
and a similar pattern was observed among the peptides from 
B'2701, B'2702, and B'2703, although its abundance at cycle 
1, relative to other cycles, was lower in the latter subtype. 
Other significant  differences were observed in B'2704 and 
B'2706. 
An idea of the sensitivity of this approach for assessing 
Figure 3.  Radiochemical sequence analysis ofArg-labeled  peptide pools 
from HLA-B27 mutants obtained from internally labeled CIR transfec- 
rant cells. Data are plotted as explained in Fig. 1. dpm loaded into the 
sequencer  were  20,000  (Yg,  N63,  V67,  Q70,  and  YgQ70),  16,000 
(A24V67),  15,000 (A24),  and 12,000 (M45).  Total dpm recovered after 
sequencing  are given in parenthesis  within each panel. 
the relatedness among peptide pools from different HLA mol- 
ecules can be obtained by comparing the B27-associated se- 
quencing profiles with those from HLA-A2-bound peptides 
(Fig. 4). Clear differences were observed in the distribution 
of particular residues in A2- relative to B27-bound peptides. 
An example is the significant  presence of Ile and Met, and 
the great predominance of Leu, at position 2 relative to other 
peptide positions. 
Discussion 
The results in this study show that radiochemical pool se- 
quencing of metabolically labeled peptides can be used to es- 
tablish the anchoring side chain motifs of the endogenous 
peptides bound to a given HLA molecule, as well as to detect 
differences among the peptide pools bound to closely related 
HLA subtypes. The anchoring motif  appears as a highly pre- 
dominant radioactivity peak at a given position when the 
peptide pool is labeled with the corresponding amino acid, 
and is associated with lack of significant radioactivity at that 
position when the peptides are labeled with other amino acids. 
If an anchoring motif is not a single amino acid, but several 
ones, a prominent radioactivity signal at the corresponding 
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Figure 4.  Radiochemical  sequence analysis of internally labeled peptide pools from B'2701 to B'2706 and from A*0201. The labeled amino acid 
used in each set of experiments is denoted by its single-letter code at the end of each row. Thus, K, L, I, V, and M designate the set of sequences 
of Lys-, Leu-, lie-, Val-, and Met-labded peptide pools, respectively.  Data are plotted as exphined in Fig. 1. Radioactivity loaded into the sequencer 
ranged from 6,000 to 34,000 dpm. This difference  results from multiple factors, including the amino acid used, its specific activity, the fraction of 
the total peptide pool hbded with a given amino acid, and the average number of labeled residues among relevant peptides. Total dpm recovered  after 
sequencing are given in parenthesis within each panel. Leu- and lie-associated radioactivity at cycle  2 in the B'2701 peptide pool appears to be higher 
than expected from carry-ores. Although no assignment can be done, the possibility that this might reflect the occurrence of these residues at cycle 
2 in some peptides should be left open. 
position is observed with those amino  acids,  as shown for 
HLA-A2. 
Radioactivity peak heights depend on the relative frequency 
of a particular residue along the various peptide positions. 
Thus, peptide pools from different HLA specificities bearing 
different anchoring motifs are easy to distinguish because the 
corresponding anchorage residues will give very prominent 
radioactivity  at  the  corresponding  position.  By  contrast, 
labeling with residues that  are frequent at many positions 
may obscure existing differences among peptide pools. 
618 
Jardetzky et al. (11) have reported a predominance of basic 
amino acids at position 9 in B'2705-bound peptides. They 
were not detected with this method, probably reflecting the 
loss of sensitivity inherent  to sequencing carboxy-terminal 
peptide residues. This loss is very dependent on the nature 
of the two last residues of the peptide.  However, radioac- 
tivity at cycle 9 was sometimes observed, for instance with 
Leu-labeled peptides. 
As expected from the precise fit of pocket B  in B'2705 
for Arg (7),  the peptides bound to the B'2701  to B'2706 
Peptide Presentation by HLA-B27 Subtypes and Mutants subtypes possessed the R2 motif, indicating that this is solely 
dictated by the structure of pocket B and is not significantly 
influenced by subtype polymorphism. The frequency of Argl, 
relative to Arg2, was not significantly altered either by sub- 
type polymorphism, even in B'2703,  which differs from 
B~  by having His instead of Tyr at position 59, in pocket 
A (12). This result indicates  that His59 does not interfere 
with the presence of Arg at peptide position 1, and is com- 
patible with crystallographic data (7) showing that residue 
59 interacts with the peptide amino terminus, the Pl side 
chain pointing away from pocket A. 
The absence of the R2 motif in the peptides bound to the 
M45 mutant agrees with the crystallographic model showing 
the importance of charge complementarity between Glu45 
in HLA-B27 and the guanidinium group of the peptidic Arg2 
(7). If peptides having the R2 motif  can still bind to the M45 
mutant, they must be a minor fraction of the M45-bound 
peptide pool or bind at very low cell surface density. Neverthe- 
less, in a previous study (15) we reported that a substantial 
fraction (>40%) of anti-B*2705 alloreactive CTL crossreacted 
with the M45 mutant. If it is assumed that peptides are in- 
volved in allorecognition, a likely explanation for such fre- 
quent crossreactivity  is that, to a large extent, it is mediated 
by unrelated peptides having the same or similar side chains 
at those positions that interact with the TCR. This possi- 
bility was previously suggested to explain unexpected cross- 
reactions with the M45 mutant (15, 21). Thus, although re- 
sidual  binding of R2-containing peptides might perhaps 
account for CTL crossreaction with M45 in some cases, the 
present results strongly suggest that determinant mimicry 
by nonidentical peptides may be frequent. This is compat- 
ible with the extensive variability allowed to HLA-bound pep- 
tides at those positions not interacting with HLA pockets 
(10, 11) 
It has been proposed that  ankylosing  spondylitis  may be 
related  to a  B27-directed  autoimmune T cell  response  trig- 
gered  by  external  pathogens  carrying  crossreactive  T cell  de- 
terminants  (22).  The idea  that  T cell  deterrLfinant  mimicry 
by nonidentical  peptides  may not be infrequent  adds a new 
dimension to this  hypothesis,  as crossreactivity  would not 
necessarily  involve  a  bacterial  peptide  highly  homologous to 
a  B27-bound endogenous peptide,  but  just  one sharing  cer- 
tain  residues  amenable to interacting  with the TCR. 
Conservation  of  the  K2 motif  among the  peptides  bound 
to  the  Y9 and  A24 mutants was somewhat surprising  on the 
basis  of  structural  evidence  showing the  involvement  of  His9 
and Thr24 in  the  network of  hydrogen bonds that  stabilizes 
the  peptide  K2 side  chain  in  pocket  B (7).  Both the  Y9 and 
A24 mutations  disrupt  this  network. Nevertheless,  it  is  clear 
from our data  that  such  disruption  is still  compatible  with 
many peptides  carrying  the  R2 motif.  Thus,  straight  extrapo- 
lations  from x-ray  models or from model building  calcula- 
tions  regarding  the effect  of single  residue  changes on pep- 
tide  binding  must  be  done with  great  caution,  as  these  effects 
may not be easy  to predict.  Conservation of  the R2 motif 
does  not imply that  all  the  peptides  that  bind to  B~  will 
also  bind to  these  mutants.  Indeed,  A24 was not recognized 
by 50% of the anti-B~  CTL tested in a previous study 
(15), suggesting that many peptides bound to B~  cannot 
bind to this mutant, at least in a way that can be recognized 
by the same CTL. Although the Y9 mutation can also affect 
binding of some peptides, we have observed very frequent 
crossreactivity between this mutant and B~  with aUoreac- 
tire CTL (our unpublished data),  suggesting that most en- 
dogenous peptides that bind to B~  can still bind to the 
Y9 mutant. The conservation of the R2 peptide motif in 
the V67 and Q70 mutants is consistent with the relatively 
conservative nature of the substitution at residue 67, which 
also has little effect on allorecognition (15), and with the orien- 
tation of the side chain at position 70, away from pocket B 
(7). These data do not exclude the possible presence of other 
P2 side chains in some of the peptides bound to these mu- 
tants, as some of the mutations could relax  the restrictive 
character  of the B pocket. 
Glu63 in HLA-B27 is located in the rim of pocket B and 
interacts with peptidic main chain atoms (7). The conserva- 
tion of the R2 motif among the peptides bound to the N63 
mutant indicates that Glu63 is not required for maintaining 
this motif, and is consistent with crystallographic data showing 
no interaction of this residue with the R2 side chain. The 
strikingly low signal for Arg at position 1 among the pep- 
tides bound to the N63 mutant strongly suggests a direct 
effect of this mutation on disrupting the contacts that stabi- 
lize amino-terminal Arg residues. Such disruption would affect 
the interaction between Glu63 and Arg62, and through this, 
the interaction between Arg62 and Glu163, which interacts 
with the peptide R1  (7). 
Comparison of the sequence profiles of the peptide pools 
from B'2701 to B~  suggests that B27 subtypes share 
a  significant  number of bound  peptides,  but  many R2- 
containing peptides either bind to only some subtypes or they 
bind to all the subtypes but with greatly different efficiency. 
This is in agreement with functional studies showing fre- 
quent crossreactivity,  but also differential recognition, of HLA- 
B27 subtypes with anti-B~  CTL (14, 23).  Substantial 
differences among peptide pools from two HL.A-A2 subtypes 
have also been recently reported (24). Differences among the 
peptide pools from B27 subtypes are due to the location of 
subtype polymorphism in areas of the molecule that interact 
with bound peptides.  However,  the differences seen in se- 
quence patterns do not only affect those peptide residues in- 
teracting with the pockets in which subtype changes are lo- 
cated, but also other peptide positions, including those whose 
side chains point away from the groove. Thus, sequence pat- 
terns reflect the global alteration of the peptide pool. The 
present results demonstrate the importance of pockets other 
than the B pocket in shaping the repertoire of peptides that 
can bind to a particular class I HLA protein. This must be 
emphasized because it means that, in spite of the major con- 
tribution of the interaction with the peptide main chain and 
the R2 side chain, many peptides having the R2 motif will 
bind to HLA-B27 variants only if the structure of other pockets 
is maintained unaltered. 
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